Evidence map›Paper›PMID 37845829›Full record

ArticleESC heart failure2024

Role of ejection fraction in patients at risk for advanced heart failure: insights from the HELP-HF registry.

Matteo Pagnesi, Carlo Mario Lombardi, Chiara Tedino, Mauro Chiarito, Davide Stolfo, Luca Baldetti, Marianna Adamo, Filippo Calì, Riccardo Maria Inciardi, Daniela Tomasoni and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Gut microbiota's role in heart failure.Heart failure reviews · 2025
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 5 institutions in 2 countries.

Matteo PagnesiInstitute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.ORCID https://orcid.org/0000-0002-9298-7871
Carlo Mario LombardiInstitute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Chiara TedinoInstitute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Mauro ChiaritoHumanitas Research Hospital IRCCS, Milan, Italy.
Davide StolfoCardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.
Luca BaldettiCardiac Intensive Care Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Marianna AdamoInstitute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Filippo CalìInstitute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Riccardo Maria InciardiInstitute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Daniela TomasoniInstitute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Ferdinando LoiaconoHumanitas Research Hospital IRCCS, Milan, Italy.
Marta MaccalliniHumanitas Research Hospital IRCCS, Milan, Italy.
Alessandro VillaschiHumanitas Research Hospital IRCCS, Milan, Italy.
Gaia GaspariniHumanitas Research Hospital IRCCS, Milan, Italy.
Marco MontellaHumanitas Research Hospital IRCCS, Milan, Italy.
Stefano ContessiCardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.
Daniele CocianniCardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.
Maria PerottoCardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.
Giuseppe BaroneCardiac Intensive Care Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Marco MerloCardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.
Alberto Maria CappellettiCardiac Intensive Care Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Gianfranco SinagraCardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.
Daniela PiniHumanitas Research Hospital IRCCS, Milan, Italy.
Marco MetraInstitute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.ORCID https://orcid.org/0000-0001-6691-8568
Surgical Specialties (Canada) · CAUniversity of Trieste · ITHumanitas University · ITVita-Salute San Raffaele University · ITIRCCS Humanitas Research Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsPatients with heart failure (HF) with reduced ejection fraction (EF) (HFrEF), mildly reduced EF (HFmrEF), and preserved EF (HFpEF) may all progress to advanced HF, but the impact of EF in the advanced setting is not well established. Our aim was to assess the prognostic impact of EF in patients with at least one 'I NEED HELP' marker for advanced HF. METHODS AND

resultsPatients with HF and at least one high-risk 'I NEED HELP' criterion from four centres were included in this analysis. Outcomes were assessed in patients with HFrEF (EF ≤ 40%), HFmrEF (EF 41-49%), and HFpEF (EF ≥ 50%) and with EF analysed as a continuous variable. The prognostic impact of medical therapy for HF in patients with EF < 50% and EF > 50% was also evaluated. All-cause death was the primary endpoint, and cardiovascular death was a secondary endpoint. Among 1149 patients enrolled [mean age 75.1 ± 11.5 years, 67.3% males, 67.6% hospitalized, median follow-up 260 days (inter-quartile range 105-390 days)], HFrEF, HFmrEF, and HFpEF were observed in 699 (60.8%), 122 (10.6%), and 328 (28.6%) patients, and 1 year mortality was 28.3%, 26.2%, and 20.1, respectively (log-rank P = 0.036). As compared with HFrEF patients, HFpEF patients had a lower risk of all-cause death [adjusted hazard ratio (HR

conclusionsAmong patients with HF and at least one 'I NEED HELP' marker for advanced HF, left ventricular EF is still of prognostic value.

Indexed as

Heart FailureCause of DeathFemaleHumansInfantMaleRegistriesRisk FactorsStroke VolumeAdvanced heart failureEjection fractionHeart failureHFmrEFHFpEFHFrEF

Identifiers

PMID37845829
PMCPMC10804181
OpenAlexW4387692873

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.